Skip to the main content.

KBI in the News | AdAlta secures key manufacturing agreements for AD-214

Picture of Admin Admin Aug 28, 2018 9:27:01 AM

News

KBI in the News | AdAlta secures key manufacturing agreements for AD-214

MELBOURNE Australia, 5 June 2018, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate toward clinical development, is pleased to announce that it has secured agreements critical to the development of its lead therapeutic program, AD-214. Selexis SA has been appointed for cell line development. KBI Biopharma, Inc. has been appointed for process development, analytical development, formulation development, and clinical manufacturing services.

Read Full Press Release from AdAlta (PDF)

 

 

 

 

 

 

 
KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

Admin: Apr 15, 2024 7:55:00 AM

Durham, North Carolina (April 15, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and...

Read More
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

Admin: Apr 1, 2024 7:55:00 AM

Durham, North Carolina (April 1, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing...

News
Read More
KBI Biopharma Recognized as a Leader in All Six Categories of the 2024 CDMO Leadership Awards

KBI Biopharma Recognized as a Leader in All Six Categories of the 2024 CDMO Leadership Awards

Picture of KBI Biopharma KBI Biopharma: Mar 21, 2024 11:19:28 AM

KBI Biopharma, a JSR Life Sciences Company and leading global Contract Development and Manufacturing Organization (CDMO) has received six awards in...

News
Read More